AAO: Two-Year VITA Follow-Up of Avisi’s VisiPlate Presented

Overview

Avisi Technologies presented two-year follow-up from the VITA clinical trial of its investigational VisiPlate aqueous shunt at the 2026 American Academy of Ophthalmology Annual Meeting. The source describes the study design and device but does not report numerical two-year efficacy or safety outcomes.

Background

VisiPlate is an investigational ultrathin, multichannel aqueous shunt being developed to lower intraocular pressure in patients with open-angle glaucoma. It is designed to drain aqueous humor from the anterior chamber. Its microchannels are intended to maintain aqueous flow while reducing the risk of obstruction, and the device is designed to be considerably thinner than conventional glaucoma drainage implants.

Data Highlights

Key Findings

• Jonathan S. Myers presented the VITA two-year follow-up at an AAO poster session on October 11, 2026.
• VITA is a prospective, single-arm, multicenter, open-label trial evaluating VisiPlate in patients with primary open-angle glaucoma at three sites in South Africa.
• VisiPlate is an ultrathin, multichannel aqueous shunt designed to drain aqueous humor from the anterior chamber. Its microchannels are intended to maintain flow while reducing the risk of obstruction.
• The supplied article context does not report numerical two-year efficacy or safety results.
• Avisi is continuing VisiPlate development through a US clinical program, including an ongoing investigational device exemption study.

Clinical Implications

The supplied article context reports that two-year follow-up was presented but does not provide efficacy values or detailed adverse-event data. It therefore does not provide results with which to assess VisiPlate’s clinical efficacy or safety.

Conclusion

The VITA presentation adds a two-year follow-up time point to the reported clinical development of VisiPlate. The supplied article context does not include the efficacy or safety results.

Related Resources & Content

1. The Ophthalmologist, 2026 — AAO VisiPlate Shows Staying Power
2. American Academy of Ophthalmology, 2026 — Primary Open-Angle Glaucoma Preferred Practice Pattern®
3. Glaucoma Physician, 2025 — FDA Clears Study for Avisi Aqueous Shunt
4. Retinal Physician — Four-Year Data Show Durable MCO-010 Effect Recommendations
5. retinal physician — Sura Vec Shows Promise in NPDR
6. the ophthalmologist — AAO Recap: 3.5-Year Observations from the GATHER2 Open-Label Extension (OLE) Trial
7. Primary Open-Angle Glaucoma Preferred Practice Pattern®
8. AAO VisiPlate Shows Staying Power
9. FDA Clears Study for Avisi Aqueous Shunt
10. Efficacy and safety of trabeculectomy versus micro-invasive glaucoma procedures (MIGPs) in managing glaucoma: a systematic review and meta-analysis | European Journal of Medical Research | Springer Nature Link